1d
Gene Editing Has Struggled To Go Commercial. This Nobel Laureate Has A $1 Billion Plan To Fix That.
Crispr’s ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer ...
Investors have bought into the promise of CRISPR technology for years. The ability to target and edit genes to treat cancer and various genetic conditions is an obvious home run. CRISPR Therapeutics ...
Scientists are testing an entirely new way to fight heart disease: whether gene editing might offer a one-time fix for high ...
SOUTH SAN FRANCISCO, Calif. & MADISON, Wis., February 18, 2026--Cellares, the first Integrated Development and Manufacturing ...
Eli Lilly (NYSE:LLY) reached a second milestone in its CRISPR gene editing collaboration with Scribe Therapeutics, advancing programs in neurological and neuromuscular diseases. The company reported ...
With a shared purpose, we can realize the true promise of CRISPR and improve healthcare, providing hope to more patients with ...
Dr. Rebecca Ahrens-Nicklas and Dr. Kiran Musunru crafted a bespoke treatment that has successfully corrected the genetic ...
For most of his 20 years, a New Jersey man knew pain as a daily reality. Now, after a one-time CRISPR gene-editing treatment at Children's Hospital of Philadelphia, Austin Louis says he is finally ...
A research team has successfully demonstrated the world's first gene-editing treatment for Leber's hereditary optic ...
The idea of self-amplifying gene editing is to get cells to pass on packages of CRISPR machinery to their neighbours, boosting the effect ...
CRISPR gene editing has transitioned from a laboratory curiosity to a cornerstone of modern biotechnology, revolutionizing our approach to genetic diseases, including Charcot-Marie-Tooth (CMT) disease ...
A sales partner offered a ray of hope that this company couldn't for itself.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results